With new app for FDA approval, Gilead aims for a hep C trifecta

Gilead Sciences ($GILD), already reaping billions from its duo of approved hepatitis C therapies, has submitted a third pill to the FDA. The combination therapy, which has the agency's breakthrough designation, promises to cure a wider range of patients with the virus. Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.